Search Results

Goldberger brings over 40 years of pharmacy practice and pharmaceutical industry experience and has most Goldberger has most recently been with Otsuka where he led the Regulatory Affairs efforts to gain approval In addition, he led CMC Regulatory Affairs, Labeling, Regulatory Operations/Technology and Medical Writing (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

“There is such a significant unmet medical need around the globe caused by Alzheimer’s disease and patients I look forward to his guidance and contributions assisting our dedicated team in the process of bringing (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Management will host a conference call on Monday, December 28th, 2020 at 4:30 pm Eastern Time to review Conference Call / Webcast Information: The live webcast of the conference call can be accessed online at https (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors and Media

A live audio webcast of the presentation will be available at http://wsw.com/webcast/cantor7/avxl/. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

Anavex plans to submit the data for publication in a peer-reviewed medical journal. “Rett syndrome is a devastating, non-inherited genetic post-natal progressive neurodevelopmental disorder Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

of patients with the highest ANAVEX ® 2-73 concentrations point towards the continued ability of the medication (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

Company to host a webcast today at 8:30 a.m. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://www.fda.gov/regulatory-information /search-fda-guidance-documents/early-alzheimers-disease-developing-drugs-treatment [2] https://www.braincouncil.eu

A live audio webcast will be accessible at https://wsw.com/webcast/needham117/avxl/2272873 or through (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://www.braincouncil.eu

Professor Aarsland earned medical degrees from Universities of Bochum, Germany and Oslo, Norway, with in the ongoing Parkinson’s disease dementia Phase 2 study, since there is such a significant unmet medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

A live audio webcast will be accessible at https://journey.ct.events/view/d7873309-2f78-4c44-8956-1d45574a7435 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most